Inspire Singapore Study

NCT06540716 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-05-22

No results posted yet for this study

Summary

Prospective, multicenter, open-label study designed to confirm device performance of Inspire system in Singapore.

Conditions

Interventions

DEVICE

Inspire System

Hypoglossal nerve stimulation therapy will be activated at approximately 1 month post-implant.

Sponsors & Collaborators

  • Inspire Medical Systems, Inc.

    lead INDUSTRY

Principal Investigators

  • Toh Song Tar, MD · Singapore General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-25
Primary Completion
2025-07-17
Completion
2025-12-01
FDA Device
Yes

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06540716 on ClinicalTrials.gov